[ad_1]
The Amsterdam-based European Medicines Agency (EMA) said on Wednesday that it was still considering whether a second vaccine against coronavirus infection should be allowed in the EU. Last month, the agency authorized community distribution of the COVID-19 vaccine, developed by BioNTech and Pfizer.
“EEA Committee for Medicinal Products for Human Use [CHMP] The debate on the Modern vaccine against COVID-19 has not been completed today. They will continue on Wednesday, the agency said in a statement. “The EEA will make no more announcements today.”
Under pressure from EU members over the deteriorating epidemiological situation, the EEA had previously decided to present a decision originally scheduled for January 12.
The EEA stated that it would issue an appropriate notice without delay, “if the CHMP ends today [pirmadienio] the meeting will take place [bendrą] opinion “.
As demonstrated by clinical trials with 30.4 thousand. The efficacy of the vaccines in the Modern American company is 94.1% compared to the placebo group.
The modern vaccine would be the second to be licensed in the European Union. On December 21, the EVA authorized the distribution of the COVID-19 vaccine, developed by BioNTech and Pfizer, under an expedited procedure.
However, last week, the EVA said it is unlikely that the coronavirus vaccines developed by the British company AstraZeneca and the University of Oxford, which were approved in the UK last Wednesday, could be distributed in the European Union until next month.
With the approval of two vaccines each by Britain and the United States, the EEA has come under pressure to speed up its procedures. Germany was under special pressure.
Pfizer-BioNTech’s vaccination campaign in the EU started on December 27, but at a much slower pace than in the United States, Britain or Israel.
The European Commission defended the bloc’s strategy early Monday, saying its plans would help the EU overcome “obstacles along the way.”
“Obviously, such a complex ambition will always bring difficulties,” EC spokesman Eric Mamer told reporters.
The European Commission highlighted that it had commissioned “almost 2 billion euros. six types of vaccines. This number is four times higher than the population of the EU.
The United States is currently vaccinated with Pfizer-BioNTech and Moderna, and the United Kingdom has also started vaccinating British pharmaceutical giant AstraZeneca on Monday.
Vaccination in EU countries is much slower than expected. In France, for example, only more than 500 people received the first dose of the vaccine. Germany, in turn, began vaccinating 200,000. people.
The Netherlands, the last country to start vaccination in the EU, has announced that the start of vaccination will be brought forward two days and the first doses will be administered on Wednesday.
[ad_2]
